


THIRD EDITION

Recurrent Pregnancy Loss



Editors
Mala Arora
Neelanjana Mukhopadhaya

Foreword
Lesley Regan



Contents

SECTION 1: INTRODUCTION

1. Overview and Terminology Clarified 3
Mala Arora
2. Cytokines and the Success or Failure of Pregnancy 7
Raj Raghupathy

SECTION 2: GENETIC CAUSES

3. Overview of Genetic Causes 19
Laura Kasak, Kristiina Rull, Maris Laan
4. Single Gene Disorders and Telomeric Deletions 27
Carmen M García-Pascual, Pilar L Iglesias, Carmen R Lluesa
5. Preimplantation Genetic Testing: An Evidence-based Update 32
Santanu Acharya
6. Male Factors 39
Madhuri Patil
7. Sperm DNA Fragmentation Index 45
Chinyerum S Opuwari, Ralf R Henkel, Ashok Agarwal

SECTION 3: ENDOMETRIAL CAUSES

8. Endometrial Factors 57
Kimberley Nash, Pushpakala A Maharajan
9. Endometrial Receptivity Array 61
Shalu Gupta, Shivani Singh

SECTION 4: SYSTEMIC CAUSES

10. Antiphospholipid Syndrome 67
Narinder Pal, Shruti Arora
11. Autoimmune Disorders 73
Narinder Pal, Shruti Arora
12. Hyperhomocysteinemia 79
Mala Arora, Ritu Jain
13. Inherited Thrombophilia 83
Shachi Mishra
14. Endocrinal Causes 86
Alka Prakash
15. Polycystic Ovarian Syndrome 91
Jude Jose
16. Poor Oocyte Quality—Ovarian Aging 94
Jane Ding, Jyotsna Pundir

SECTION 5: ANATOMICAL CAUSES

- | | |
|--|-----|
| 17. Anatomical Factors | 103 |
| <i>Asher Bashiri, Maor Kabessa, Arsen Gvenetadze, Isca Atar, Anatte E Karmon</i> | |
| 18. Endometriosis | 112 |
| <i>Sanjivni Khanna</i> | |
| 19. Adenomyosis | 125 |
| <i>Sanjivni Khanna</i> | |
| 20. Intrauterine Adhesions | 140 |
| <i>Nozer Sheriar, Rajneet Bhatia</i> | |
| 21. Cervical Cerclage: Benefits and Controversies | 146 |
| <i>Neelanjana Mukhopadhaya, Rumana Rahman</i> | |
| 22. Role of Endoscopy | 151 |
| <i>Hafeez Rahman, Nikita Trehan</i> | |

SECTION 6: INFECTIONS

- | | |
|--|-----|
| 23. Latent Genital Tuberculosis and Subclinical Endometritis | 165 |
| <i>Shyam P Jaiswar, Swati Gautam</i> | |
| 24. Treatment of Female Genital Tuberculosis | 171 |
| <i>JB Sharma, Sona Dharmendra, Shefali Agarwal, Eshani Sharma, Karishma Thariani</i> | |
| 25. Sexually Transmitted Diseases: Chlamydia, Syphilis, and HIV | 176 |
| <i>Lucy Coyne, Niranjani L Ramachandran, Sanjeev Sharma</i> | |
| 26. Bacterial Vaginosis | 180 |
| <i>Ramesh Kuppusamy, Dilip Visvanathan, Tony A Hollingworth</i> | |
| 27. Natural Killer Cells | 185 |
| <i>Srividya Seshadri, Rohan Palshetkar, Paul Serhal, Wael Saab</i> | |

SECTION 7: MISCELLANEOUS

- | | |
|--|-----|
| 28. Obesity | 191 |
| <i>Naama Steiner, Lindsey A Choi, Gary Levy, Asher Bashiri</i> | |
| 29. Late Pregnancy Loss | 196 |
| <i>Bruce K Young</i> | |
| 30. Immune and Nonimmune Fetal Hydrops | 202 |
| <i>Kathryn Killicoat, Antony A Hollingworth</i> | |
| 31. Recurrent Molar Pregnancies | 207 |
| <i>Rosemary A Fisher, Neil J Sebire</i> | |
| 32. Recurrent Implantation Failure and Biochemical Pregnancies | 215 |
| <i>Nalini Mahajan, Jasneet Kaur, Neha Pruthi</i> | |
| 33. Psychoneuroimmunology: Role of Stress | 222 |
| <i>Petra C Arck, Maike K Knackstedt</i> | |

SECTION 8: MANAGEMENT OPTIONS

- | | |
|---|-----|
| 34. Role of Progesterone | 229 |
| <i>Ioannis D Gallos, Arri Coomarasamy</i> | |
| 35. Role of Dydrogesterone | 233 |
| <i>Ashok Kumar, Simar Kaur</i> | |
| 36. Role of Granulocyte Colony-stimulating Factor | 239 |
| <i>Fabio Scarpellini, Marco Sbracia</i> | |

37. Role of <i>In Vitro</i> Fertilization <i>Neeta Singh, Anshu Yadav</i>	243
38. Role of Lymphocyte Immunotherapy <i>Alric V Mondragon, Lara Theresa A Aleta</i>	247
39. Oxidative Stress and Role of Antioxidants and Micronutrients <i>Harlev Avi, Sarah K Fatool</i>	250
40. Role of Tender Loving Care <i>Mala Arora</i>	256
41. Management of Patient with Multiple Treatment Failures <i>Howard JA Carp</i>	258

SECTION 9: ROLE OF ULTRASOUND

42. Scanning the Nonpregnant Patient <i>Ashok Khurana</i>	267
43. Early Pregnancy and Reassurance Scans <i>Kuldeep Singh</i>	277

SECTION 10: FAILED PREGNANCY

44. Role of Embryoscopy, Fetal Karyotyping, and Placental Biopsy <i>Vasilios Tanos, Demetra Georgiou, Kelsey E Berry, Eleftherios Meridis, Minas Paschopoulos</i>	289
45. Surgical versus Medical Evacuation <i>Mala Arora</i>	296
46. Grief Counseling in Recurrent Pregnancy Loss <i>Taswin Kaur, Kamini A Rao</i>	300
47. Medicolegal Implications <i>Usha Ahluwalia</i>	303

APPENDICES

Appendix 1: Role of Dehydroepiandrosterone <i>Neelanjana Mukhopadhaya</i>	313
Appendix 2: Role of Uterine Stem Cells <i>Mala Arora</i>	314
Appendix 3: Are Epigenetic Factors Responsible for Recurrent Pregnancy Loss? <i>Mala Arora</i>	315
Appendix 4: Thromboelastography and Recurrent Pregnancy Loss <i>Jyoti Mishra, Manju Puri</i>	316
Appendix 5: Diagnostic Tests for Autoimmunity and Alloimmunity <i>Mala Arora</i>	319
Appendix 6: Algorithm on Clinical Management of Recurrent Pregnancy Loss <i>Mala Arora</i>	320
<i>Index</i>	323

Overview and Terminology Clarified

Mala Arora

INTRODUCTION

Percy Malpas from Liverpool coined the term “habitual aborter” for women with three or more consecutive abortions.¹ The term is no longer used because of its negative connotations. The word abortion is now replaced by miscarriage,² (Table 1) which is defined as the loss of a pregnancy less than 20 weeks gestation or loss of a fetus weighing less than 500 g.² The traditional definition of three consecutive miscarriages was proposed by Malpas and seconded by Eastman³ who in 1946 worked on a community based statistical model and proposed that the group with two losses had a significantly better pregnancy outcome than the group with three or more losses. Further studies by Stirrat confirmed this observation.⁴ However, authors personal observations⁵ and many other observational studies⁹ confirm that pregnancy outcome is no different in the more than two and more than three miscarriage groups.

Royal College of Obstetrics and Gynecology (RCOG) UK continues to define recurrent pregnancy loss (RPL) as three or more consecutive pregnancy losses.⁶ The European Society for Human Reproduction and Embryology (ESHRE) special interest group for early pregnancy defined recurrent miscarriage as three early consecutive losses or two late pregnancy losses.⁷ However the American College of Obstetrics and Gynecology (ACOG)⁸ modified the definition to two or more pregnancy losses confirmed by ultrasound or histopathology of the products of conception. Some others

consider RPL to be defined as two or more consecutive miscarriages OR three spontaneous miscarriages which may not be consecutive.

The ACOG definition is clinically more relevant as most clinicians would start investigations for RPL after two consecutive losses. However this would increase the prevalence of RPL to 5% as compared to previous 1% with three or more losses. It would also favorably skew the effect of treatment modalities. Hence it is thought that for research and publication purposes, we retain the definition of three or more losses. Logically, it will be hard to retain the RCOG definition, as changing trends in clinical practice will generate data accordingly. However, this heterogeneity in definition hinders scientific research and gives birth to varying clinical practices globally. Table 2 outlines the heterogeneity of definition in published studies.

The current definition does not include women with ectopic, biochemical pregnancies and pregnancy of uncertain location which has similar emotional consequences for the couple. Each of these conditions is known to be associated

TABLE 1 Old and new nomenclature

Previous term	Recommended term
Spontaneous abortion	Miscarriage
Threatened abortion	Threatened miscarriage
Inevitable abortion	Inevitable miscarriage
Incomplete abortion	Incomplete miscarriage
Complete abortion	Complete miscarriage
Missed abortion	Missed miscarriage
Blighted ovum	Early fetal demise
Septic abortion	Miscarriage with sepsis
Recurrent abortion	Recurrent miscarriage

TABLE 2 Summary of definitions of recurrent miscarriage used in clinical trials

Reference	Definition of recurrent pregnancy loss
Cowchock, 1992	≥2 fetal losses
Silver, 1993	≥1 unexpected fetal death >12 weeks gestation OR ≥2 unexplained first trimester losses
Kutteh, 1996	≥3 consecutive pregnancy losses
Laskin, 1997	≥2 consecutive fetal losses at <32 weeks
Rai, 1997	≥3 consecutive miscarriages
Pattison, 2000	≥3 miscarriages
Farquharson, 2002	>2 fetal losses
Triolo, 2003	≥3 consecutive fetal losses <10 weeks gestation
Clark, 2010	≥2 consecutive fetal losses at <24 weeks gestation

Source: From Bhattacharya S. Recurrent miscarriage: should the definition be revised? In: Arora M, Bhattacharya S, Kumari V (Eds). World Clinics Obstetrics and Gynecology Recurrent Miscarriage. 2011;1(1):136.

with a poor obstetric outcome and can be recurrent. Hence the proposal is that we should include ultrasound, histopathological and biochemical evidence of a pregnancy". We may have to set a minimum level of β -human chorionic gonadotropin (β -hCG) positivity so as to exclude drug-induced positive β -hCG levels in assisted reproductive technique (ART) pregnancies.

Recurrent implantation failure and Pre clinical pregnancy loss/very early pregnancy loss (VEPL) are markers of poor implantation and have a common spectrum with RPL. However the current definition does not take this into consideration. This is because both these entities are in themselves not clearly defined and hence data collection can be skewed. I sincerely feel that this should be part of the definition of RPL. Pre clinical losses with documented beta HCG rise and fall are a clear indication of failed implantation and may result from genetically abnormal embryos. This is the reason why some authors believe that rather than the number of losses, the time to take home a baby from the time of first pregnancy event should also be taken into consideration in the definition.


Recurrent implantation failure (RIF) defined as no implantation after replacement of 10 grade-A embryos of day 2/3 maturity or 4 blastocyst of day 5 maturity, fresh and frozen cycles included. A standard definition is still lacking. This is an entity distinct from RPL, although they both have many overlapping causes. They may be described as two ends of the same spectrum (Fig. 1). Recurrent implantation failure is only relevant in the setting of assisted conception cycles, whereas RPL is usually seen in spontaneous conceptions. However women with RIF will need to be evaluated for most causes of RPL as well as laboratory factors as well as the synchronization with the window of implantation which is not relevant to RPL.

Primary recurrent miscarriages are two or more losses with no pregnancy progressing beyond 20 weeks.

Secondary recurrent miscarriages are two or more losses after a pregnancy that has progressed beyond 20 weeks which might have resulted in a live or stillbirth.

This division is not so important as the etiological factors and prognosis is the same in the two groups.¹⁰ Perhaps the incidence of acquired anatomical defects like uterine adhesions and cervical insufficiency may be higher in the secondary RPL group, hence evaluation of the uterine cavity should always be done in this group.

Recurrent pregnancy loss comprises of both early and late pregnancy losses. The spectrum encompasses:



RPL, recurrent pregnancy loss; RIF, recurrent implantation failure.

Fig. 1: Relationship of recurrent pregnancy loss (RPL) and recurrent implantation failure.

- Preclinical pregnancy loss: This entity is diagnosed by performing serum β -hCG assays in the late luteal phase prior to the onset of the next menstrual cycle
- Clinical pregnancy loss is defined as pregnancy loss following an ultrasound evidence of a gestational sac. Clinical pregnancy loss is divided into:
 - Preembryonic, when no fetal pole is identified (<5 weeks)
 - Embryonic, when a fetal pole is identified (5–10 weeks) and
 - Fetal, more than 10 weeks' gestation
- First trimester loss is loss of a pregnancy less than 12 weeks. More than 80% of miscarriages occur in the first 12 weeks. This may also be addressed as recurrent miscarriages (RM) or recurrent spontaneous miscarriage
- Midtrimester loss occurs between 12 weeks and 28 weeks of pregnancy. The common causes are anatomical defects and antiphospholipid syndrome. These women will benefit with a hysteroscopic evaluation
- Late fetal loss occurs between 28 weeks to term. The most common cause is preterm labor, preterm premature rupture of membranes, preeclampsia (PE), or congenital malformations. Unexplained stillbirth is even more traumatic than unexplained RPL and merits detailed investigations to ascertain a cause (refer to chapter 29). Thrombophilia screening becomes relevant in women with midtrimester and late pregnancy losses.

For the purpose of this book late fetal loss describes pregnancy loss between 12 weeks and delivery.

Recurrent spontaneous miscarriage only deals with 1st trimester losses.

Table 3 defines terminology related to pregnancy loss as proposed by ESHRE - Special interest group for early pregnancy.¹¹

TABLE 3 ESHRE nomenclature of early pregnancy events

Term	Definition
Biochemical pregnancy loss	Spontaneous pregnancy loss confirmed by decreasing β -hCG levels but not located on ultrasound scan
Empty sac or anembryonic pregnancy loss	Intrauterine sac with absent fetal pole/yolk sac on ultrasound
Yolk sac miscarriage	Intrauterine gestational sac and yolk sac but no fetal pole on ultrasound
Embryonic miscarriage	Intrauterine gestational sac with yolk sac and fetal pole but no cardiac activity
Fetal miscarriage	Pregnancy loss >10 weeks size with a fetal pole of CRL >33 mm on ultrasound
Ectopic pregnancy	Pregnancy visualized outside the endometrial cavity
Early pregnancy loss	Pregnancy loss <10 weeks gestational age (<8 developmental week)
Late pregnancy loss	Greater than 12 weeks gestation
Pregnancy of unknown location	• No identifiable pregnancy on transvaginal scan with a β-hCG level of 1,500 IU/L • No identifiable sac with on trans-abdominal scan with β-hCG of 6,000 IU/L

β -hCG, β -human chorionic gonadotropin; CRL, crown-rum length.

Personal data from the authors subfertility clinic is presented below to emphasize the number of patients with RPL that seek assisted conception after one, two or three miscarriages (Table 4).

Pregnancy outcomes are presented in table 5.

By far the most common event is a sporadic miscarriage, which occurs in 20–30% of women, and in less than 5% after the documentation of fetal cardiac activity. Sporadic miscarriages do not compromise future obstetric outcomes.⁷ Hence, women with a single spontaneous pregnancy loss should not be investigated, as the chances of a live birth subsequently are comparable to no previous loss (Table 5).

There is no statistically significant difference in the numbers that got pregnant, in the group with two miscarriages (25/80 = 31.2%) and the group with three miscarriages (11/39 = 28.2%). The numbers that delivered were 47% in the group with two miscarriages and 42.8% in the group with three miscarriages, which is not statistically significant. As the numbers get smaller it is difficult to make meaningful conclusions.

On the basis of this evidence it was proposed to change the definition of recurrent miscarriages to two consecutive miscarriages 2007, which has now been accepted widely.

Conventionally women with RPL conceived spontaneously. However, we now have a new subgroup of women that present with infertility and RPL. They only conceive with ART. In our personal data from an infertility clinic 10% (118/1,181) of women seeking ART are patients with two or more miscarriages. Experiencing loss of an ART pregnancy is

emotionally more traumatic and these couples often have a lower threshold for investigations and treatment.

However, whether we need to investigate them after one loss or two, will depend on the time to pregnancy and the maternal age.

The link between maternal age and pregnancy loss is now well-documented. Maternal age of 35 and above is associated with a higher incidence of pregnancy loss; the incidence increases progressively with increasing maternal age.

There is a need to constantly revise investigation and treatment guidelines, for patients with RPL in the changing social and medical scenario, due to the following:

- Today women start their reproductive careers late and will not have the time and patience to wait for multiple losses.
- Subgroups of women that miscarry due to anatomical factors or antiphospholipid antibodies have well-defined treatment modalities that can reduce the rate of subsequent miscarriages. Hence to deny them this treatment till they have multiple pregnancy losses seems unjustified.

Hence, women seeking pregnancy through ART may demand to have all investigations including evaluation of the uterine cavity after one miscarriage or biochemical pregnancy.

It may also be proposed that in women greater than 37 years, one miscarriage should prompt genetic screening and replacement of a euploid embryo. Similarly RIF, abnormal gamete morphology, poor quality embryos and advanced maternal/paternal age should have sperm DNA fragmentation index (DFI) and preferably preimplantation genetic screening (PGS) of the trophoctodermal cells and replacement of only euploid embryos, prior to complete cessation of gametogenesis.

INTERPREGNANCY INTERVAL

Women with a pregnancy loss will often ask “when is it best to try again?” Although the World Health Organisation¹³ has recommended 6 months interpregnancy interval between pregnancies, there are studies to suggest that a shorter interpregnancy interval in women with RPL may have better outcomes.^{14,15} Having one normal period post a miscarriage is sufficient for a couple desperate to achieve their dreams of parenthood.

TABLE 4 Breakup of total number of patients visiting the clinic according to the number of miscarriages⁵

0	810
1	224
2	80
3	39
4	16
5	5
7	2
13	1
Total	1177

TABLE 5 Outcome in patients with 0, 1, 2, 3, and 4 miscarriages⁵

No. of abortions	Total no. of patients	No. of pregnant patients (%)	UPT + but lost to follow up	SVD/LSCS/preterm (%)	Miscarriages (%)
0	810	197 (24.32)	81	59/116 (50.86)	57/116 (49.13)
1	224	55 (24.55)	22	17/33 (51.5)	16/33 (48.48)
2	80	25 (31.25)	8	8/17 (47.0)	4/17 (23.52)
3	39	11 (28.2)	4	3/7 (42.85)	4/7 (57.14)
4	16	5 (31.25)	0	2/5 (40.0)	3/5 (60.0)

UPT, urine pregnancy test; SVD, spontaneous vaginal delivery; LSCS, lower segment cesarean section.




Fig. 2: Causes of recurrent pregnancy loss

CONCLUSION

Definition and terminology of RPL has been revised over the past few years. However, it still needs further modifications which need to be deliberated upon.

The author leaves you to ponder about the known causes of RPL (Fig. 2) and the large group so far unexplained and the discussions in the coming chapters will help us shrink this group in the near future.

REFERENCES

- Malpas P. A study of abortion sequence. *J Obstet Gynecol Br Emp.* 1938;45:932.
- National institute of Child health and human development. (2012). What is pregnancy loss/miscarriage? [online] Available from: www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002458. [Accessed January, 2018].
- Eastman NJ. Habitual abortion. In: Meigs JV, Sturgis S (Eds). *Progress in Gynaecology*, vol 1. New York: Grune and Stratton; 1946.
- Stirrat GM. Recurrent miscarriage I: Definition and epidemiology. *Lancet.* 1990;336:673-5.
- Arora M. Overview and definition in "Recurrent Pregnancy Loss" 2007. In: Arora M, Konje JC (Eds). *Recurrent pregnancy Loss*. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2007.
- The investigation and treatment of couples with recurrent miscarriages Royal College of Obstetricians and Gynaecologists green top guideline No 17 May 2011. [online] Available from: www.rcog.org.uk. [Accessed January, 2018].
- Farquharson RG, Jauniaux E, Exalto N. Updated and revised nomenclature for description of early pregnancy events. *Hum Reprod.* 2005;20:3008-11.
- Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of Recurrent Pregnancy Loss: A committee opinion. *Fertil Steril.* 2012;98:1103-11.
- Bhattacharya S. Recurrent miscarriage: should the definition be revised? In: Arora M, Bhattacharya S, Kumari V (Eds). *World Clinics Obstetrics and Gynecology Recurrent Miscarriage*. 2011;1(1).
- Bashiri A, Shapira E, Ratzon R, et al. Primary versus Secondary Recurrent Pregnancy loss-epidemiological characteristics, etiology and next pregnancy outcome. *J Perinat Med.* 2012;40: 389-96.
- Kolte AM, Bernard LA, Christiansen OB, et al. Terminology for pregnancy loss prior to viability: a consensus statement from the ESHRE early pregnancy special interest group. *Hum Reprod.* 2015;30(3):495-8.
- Nybo Anderson AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. *BMJ.* 2000;320:1708-12.
- World Health Organization. (2005). Report of a WHO technical consultation on birth spacing. [online] Available from: www.who.int/making_pregnancy_safer/documents/birth_spacing.PDF [Accessed January, 2018].
- Bentolia Y, Ratzon R, Shoham-Vardi I, et al. Effect of interpregnancy interval on outcomes of pregnancy after recurrent pregnancy loss. *J Matern Fetal Neonatal Med.* 2013;26(14):1459-64.
- Love ER, Bhattacharya S, Smith NC, et al. Effect of interpregnancy interval on outcomes of pregnancy after miscarriage: Retrospective analysis of hospital episode statistics in Scotland. *BMJ.* 2010;341:c3967.

Recurrent Pregnancy Loss

Key Features

- This is the 3rd edition of the well-received previous 2 editions of the title
- The text is extensively revised to incorporate latest research in the field
- Presentation is concise and lucid, which makes this edition more reader friendly
- The topics have been divided into various sections based on etiological factors like genetic, anatomical, infective, and immunological
- The latest diagnostic recommendations from the RCOG (UK) as well as the ACOG (USA) have been incorporated
- An updated section on "Management Options" and a well-illustrated "Role of Ultrasound" are the highlighting features of this edition
- Role of newer treatment options like IVIG, GCSF, IVF/PGS, antioxidants, and lymphocyte immunotherapy have been elaborated
- Chapters are contributed by original researchers in the field from across the world
- This book will form an excellent resource for gynecologists, specialists in reproductive medicine, teaching faculty, and postgraduate students.

Mala Arora

FRCOG (UK) FICOG FICMCH

Chairperson, Indian College of Obstetricians and Gynecologists

Director, Noble IVF Centre, Faridabad, Haryana, India

Consultant, Fortis La Femme, Greater Kailash, New Delhi, India



Neelanjana Mukhopadhyaya

DGO FICOG FRCOG DiP Med Edu

Consultant in Obstetrics and Gynecology

Honorary Senior Lecturer, University College London

Luton and Dunstable University Hospital

Luton, Bedfordshire, UK



Available at all medical bookstores
or buy online at www.jaypeebrothers.com



JAYPEE BROTHERS
Medical Publishers (P) Ltd.
www.jaypeebrothers.com

Join us on [facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)

Shelving Recommendation
OBSTETRICS & GYNECOLOGY

ISBN 978-93-5270-091-2

